UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported): April 29, 2019
ULTRAGENYX PHARMACEUTICAL INC.
(Exact Name of Registrant as Specified in Charter)
|
|
|
|
|
|
|
Delaware |
|
001-36276 |
|
27-2546083 |
|
(State or Other Jurisdiction of Incorporation) |
|
(Commission File Number) |
|
(I.R.S. Employer Identification No.) |
|
|
|
|||
60 Leveroni Court
Novato, California 94949
(Address of Principal Executive Offices, and Zip Code)
(415) 483-8800
Registrant’s Telephone Number, Including Area Code
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|
|
☐ |
Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
☐ |
Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
☐ |
Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ |
||
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered |
|
Common Stock, $0.001 par value |
RARE |
The Nasdaq Global Select Market |
|
Item 1.01 |
Entry into a Material Definitive Agreement |
Effective as of April 29, 2019, Ultragenyx Pharmaceutical Inc. (the “Company”) and Condiotti Enterprises, Inc. (the “Lessor”) entered into an Addendum 6 (the “Addendum”) to the Lease dated July 1, 2011 (the “Lease”), pursuant to which the Lease was assigned to the Company and the term was extended to December 31, 2024. The Lease, as amended by the Addendum, covers certain space located at 60 Leveroni Court, 52 Leveroni Court, and 68 Leveroni Court in Novato, CA.
The foregoing description of the Addendum is qualified in its entirety by the full text of the Addendum, a copy of which will be filed as exhibits to the Company’s Quarterly Report on Form 10-Q for the three months ended June 30, 2019.
* * *
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
Date: May 3, 2019 |
|
|
|
|
|
Ultragenyx Pharmaceutical Inc. |
||
|
|
|
|
|
|
||||
|
|
|
|
|
|
|
By: |
|
/s/ Shalini Sharp |
|
|
|
|
|
|
|
|
|
Shalini Sharp |
|
|
|
|
|
|
|
|
|
Executive Vice President, Chief Financial Officer |
- 3 -